How Much Does a GLP-1 Cost Without Insurance in 2026?

The short answer

Paying cash in 2026, a mother is generally looking at somewhere between $149 and $449 a month for an FDA-approved GLP-1 bought directly from the company that makes it. That is a genuinely different sentence from the one this page carried a year ago, when the honest answer involved four figures and a wince.

Two things changed. Both manufacturers opened self-pay pharmacies and published their prices, and in December 2025 the FDA approved an oral version, which came in at the bottom of the range. The result is that the cheapest lane and the FDA-approved lane are now, for most families, the same lane.

What has not changed is the shape of the bill. The dose you pay for in month one is rarely the dose you settle at, and the introductory number is rarely the number you are still paying in month six. Here is how the real bill takes shape. (Prices move constantly and every offer below carries an expiry date; confirm the current figure directly before you plan around it.)

What the manufacturers actually charge a cash payer

These are the companies' own published self-pay terms, checked in late July 2026 — not list prices, and not a telehealth reseller's marketing page.

Novo Nordisk's terms state that patients new to the offer "pay $199 for each month of 0.25 mg & 0.5 mg", that the "offer is for 2 monthly fills", and that the price then becomes "$349 per month" for the standard pen doses, with the Wegovy pill at "$149 for each month of 1.5 mg and 4 mg"³. Eli Lilly quotes Zepbound "as low as $299" for the 2.5 mg pen, rising by dose to $449 — and defines one month as 28 days rather than a calendar month, which quietly adds a thirteenth fill to a year⁴.

Why the pill is the cheapest door

On 22 December 2025 the FDA approved once-daily oral Wegovy, the first oral GLP-1 medicine for obesity in the US⁵. It is not a lesser product for being a tablet: in the OASIS 4 trial in the New England Journal of Medicine, oral semaglutide 25 mg produced a mean body-weight change of −13.6% at week 64 against −2.2% for placebo⁶. That sits in the same neighborhood as the injectable trials — once-weekly semaglutide produced roughly 15% mean loss in STEP 1¹ and tirzepatide near 20% in SURMOUNT-1² — while costing a third of the injectable maintenance price.

It also carries its own trade-offs, including a daily dosing routine with specific instructions and a gastrointestinal side-effect profile that was more common than placebo in the trial. Cheapest is not automatically right. But it is no longer true that the affordable option and the approved option are different options.

The dose climbs, and the invoice usually climbs with it

GLP-1 medicines work by dose, titrated upward over the first months. The headline trial results above are maintenance-dose results — what happens once you have climbed the ladder, not while you are on the bottom rung.

Look again at the table and you can see the trap in the manufacturers' own numbers. Wegovy's cash price nearly doubles the day the two-fill introductory offer ends, regardless of your dose. Zepbound's rises by $150 as you titrate from 2.5 mg to the doses that produce the trial results. Either way the bill goes up roughly as the medication starts working. Budget for the highest maintenance dose, not the hero image. We break the mechanics down in the true cost of a GLP-1 once the dose climbs.

What "difficult to afford" looks like at national scale

The numbers above are what the drug costs. What it costs people is a separate question, and one national pollster asks it directly.

In a KFF Health Tracking Poll of 1,350 US adults fielded 27 October to 2 November 2025 and published on 14 November, about one in eight adults (12%) said they were currently taking a GLP-1 drug, and women were more likely than men to say so — 15% against 9%. Among users, 56% of respondents said the drugs were difficult to afford, a share that barely moved among those with insurance (55%). About a quarter of insured users (27%) said they paid the full cost of the drugs themselves. And 14% of GLP-1 users said they were no longer using the medication because of the cost⁷.

That last figure is the one worth writing on the fridge. One in seven people who started stopped over money — not over side effects, not over disappointment with the results. Over the bill. If you are budgeting for this, you are budgeting against that statistic, and the way you beat it is by pricing the month you will still be in next spring rather than the one on the landing page.

This is a standing expense, not a one-month purchase

The most expensive assumption a mother can make is that a GLP-1 is a short push to a goal. When semaglutide was stopped and replaced with placebo in the STEP 4 trial, participants regained a substantial share of the weight they had lost⁸. So the honest cash question is not "what does one month cost" but "what does a year of this cost, at the dose that works, on a budget that has to survive the holidays and the car repair."

Where the fees hide, and what compounded really costs now

Three costs get buried. First, the dose step-up — ask the price at the highest maintenance dose. Second, membership or consult fees charged on top of the medication, sometimes billed separately so the "medication price" looks lower than your real total. Third, refill timing: Lilly's top-dose rate depends on refilling inside 45 days, so a late month can cost you the price.

That second one is not hypothetical, and the two clearest examples sit at opposite ends of the scale. Mochi Health charges $79 a month for the clinic and $99 for the drug, so the advertised number is a little over half the bill. Nurx goes further: its $79 consult and $79 monthly care fee buy no medication at all, and its own page prices the brand pens it prescribes from about $1,000 a month, collected and paid for at a pharmacy. Both disclose it. Neither leads with it.

PCOS Sisters shows the same arithmetic running the other way, and it is the version most likely to catch you out, because the medication is the part that gets quoted. Its GLP-1 prescriptions "start at $150/mo" — and in the same answer, on the same page, a membership is required to get one, at $99 or $129 a month depending on which state you live in. So the figure that travels onto comparison tables is roughly 60% of a bill that starts near $250, before labs the practice prices separately at about $335. The number a table can hold is almost never the number you pay; the only reliable fix is to ask what else is charged before the medication ships.

SynergyRx takes the same problem one step further: it doesn't publish a GLP-1 price at all. "Transparent pricing is provided after your consultation," its own site says — so there is nothing to put in a comparison table until you've already handed over your medical history. Whatever number circulates for it online came from somewhere other than the company's own page. Pomegranate Health is simpler by comparison — semaglutide "starts @ $119/mo," shown up front — but its catalog has moved since an earlier check: tirzepatide, once listed, is gone.

A different version of the same trap is the plan-length asterisk. HealthOn advertises semaglutide "starting at $189" and tirzepatide "starting at $290" — both real, but only on a 12-month plan paid upfront; month-to-month pricing isn't published anywhere we found. Vyora Wellness is the cleaner version: $299/mo semaglutide and $399/mo tirzepatide on a 4-week subscription, with its own FAQ stating the price doesn't move with dose or plan length — a shorter commitment at a higher sticker.

Four more: Care Clinics at $100/$133/mo, no pharmacy or state list. Elara Health and Wellness at $183/$268/mo, bundling labs and coaching. Spry at $199/$299/mo, confirmed via its JS bundle. Aurelius Health Group sells only microdosed tirzepatide, $89 then $199/mo.

And compounded semaglutide, long assumed to be the cheap answer, no longer reliably undercuts any of this. The FDA states that compounded drugs "do not undergo FDA's review for safety, effectiveness and quality before they are marketed" and "should only be used in patients whose medical needs cannot be met by an FDA-approved drug"⁹. When researchers ran a secret-shopper study of 75 weight-loss clinics and medical spas in two high-demand states in late 2025, 56.0% were offering compounded GLP-1s combined with B vitamins, and 4 of 21 supplying facilities (19.0%) were not licensed to perform sterile compounding¹⁰. We walk through that trade-off in full in compounded vs. brand GLP-1 on a family budget.

The cleanest cash pricing states one number that already includes the clinician and does not step up as you titrate. Whatever you land on, take it to a clinician who knows your history before your first dose — and you can compare two programs head-to-head while you decide.